In 2020, the Chinese Society of Oncology (CSCO) clearly indicated that regardless of their clinical characteristics (such as smoking history, gender, ethnicity, or others), all NSCLC patients with adenocarcinoma should be routinely tested for EGFR mutation, ALK fusion, and ROS1 fusion, and the detection of EGFR mutation should include exons 18, 19, 20, and 21 of the EGFR gene [7]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.